Indonesia Explores Stem Cell Therapies to Strengthen Its Biotechnology Ecosystem
Indonesia is exploring the development of stem cell- and secretome-based products through a partnership between state-owned PT Bio Farma (Persero) and 23 Century Medical Group Sdn Bhd. The discussions cover product registration, commercialisation and distribution in Indonesia.
The two companies signed a memorandum of understanding (MoU) in Jakarta on Friday, 9 October 2026. It was signed by Bio Farma Research and Development Director Dicky Mahardhika Taryono and 23 Century Medical Group Managing Director Datok Seri Dr David Mah.
The event was witnessed by Didi Apriadi, Special Staff to the Ministry of Investment and Downstreaming/Investment Coordinating Board (BKPM); Bio Farma President Director Shadiq Akasya; and 23 Century Medical Group CEO Dr Angelina Tiah.
The exploration marks an initial step towards assessing opportunities to develop cellular therapies and regenerative medicine in Indonesia. The process will take into account regulatory requirements, quality standards and the needs of the national health system.
The collaboration also gives the companies an opportunity to examine market readiness, regulatory issues, commercialisation models and the distribution systems needed to develop stem cell- and secretome-based products responsibly.
Bio Farma President Director Shadiq Akasya said the collaboration was a strategic move to broaden the company’s capabilities in cellular therapy and regenerative medicine, while supporting the transformation of the life sciences sector.
“For Bio Farma, developing this field is a strategic step in line with our long experience in developing vaccines and conventional pharmaceutical products. From a research and development perspective, we see this partnership as an opportunity to deepen our knowledge and build capabilities that will strengthen Indonesia’s biotechnology ecosystem,” Shadiq said, as quoted by Antara on Friday, 9 October 2026.
Shadiq also welcomed the support of the Ministry of Investment and Downstreaming/BKPM in encouraging investment in biotechnology and healthcare. He said this support was important for strengthening domestic manufacturing capabilities through strategic partnerships with international partners.
Bio Farma Research and Development Director Dicky Mahardhika Taryono said developing expertise in the field was part of a long-term effort to reinforce Indonesia’s health resilience and self-sufficiency.
He said strengthening the ecosystem would require research readiness, skilled professionals, quality systems, industry and healthcare services to be developed gradually.
“For Bio Farma, this exploration is part of an effort to build national capabilities in more advanced health technologies. We want to strengthen our understanding of the science, regulatory requirements, quality systems and industrial readiness in stages. The long-term goal is to support access to health innovations that have been proven safe and beneficial to the public,” Dicky said.
The discussions with the international partner also give Bio Farma a chance to deepen its understanding of global developments in cellular therapy and regenerative medicine.
23 Century Medical Group CEO Dr Angelina Tiah Shy Yng said medicine was increasingly moving towards treatments that focus not only on addressing symptoms, but also on repairing, restoring and improving the body’s biological functions.
“The future of medicine is moving towards therapies that focus not only on treating symptoms, but also on understanding how we can repair, restore and improve the body’s biological functions. Discussions with Bio Farma create an opportunity to understand Indonesia’s needs and requirements for stem cell- and secretome-based products, as well as memory-like natural killer cells. We hope this collaboration will be an initial step towards exploring opportunities to develop local capabilities, prioritising scientific evidence, quality, patient safety and compliance with regulatory requirements,” Dr Angelina said.
Cellular therapies and regenerative medicine are part of modern medical development, using cells and their biological derivatives to support the repair, restoration or enhancement of biological functions.
Developing this field requires broad readiness, from research and development, regulation and skilled professionals to quality systems, production technology, manufacturing facilities and healthcare services.
The exploration is part of a broader effort to expand capabilities and portfolios in life sciences and healthcare, while strengthening expertise in vaccines and biological products.
These stronger capabilities are expected to support Indonesia’s health resilience and self-sufficiency amid global advances in health technology.
Source: jawawa.id (https://jawawa.id/newsitem/indonesia-explores-stem-cell-therapies-to-strengthen-its-biotechnology-ecosystem-1791564661)
Originally published by beritasatu.com (https://www.beritasatu.com/ekonomi/3032667/indonesia-jajaki-terapi-sel-punca-untuk-perkuat-ekosistem-bioteknologi), translated from Indonesian